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A hepatitis B virus (HBV) transgenic mouse containing a naturally occurring mutation in the nucleocapsid promoter
(A1764T plus G1766A) that inhibits the retinoid X receptor a (RXRa) plus peroxisome proliferator-activated receptor a
(PPARa) heterodimer from binding to the proximal nuclear hormone receptor recognition sequence has been generated. Viral
transcription and replication occur in the liver and kidney. The nucleocapsid promoter mutation does not prevent peroxisome
proliferators from increasing viral transcription and replication in the liver of these variant HBV transgenic mice. This
suggests that peroxisome proliferators may enhance viral transcription directly in a PPARa-dependent manner through the
nuclear hormone receptor recognition site in the enhancer 1 region of the HBV genome. Hepatocyte nuclear factor 4 (HNF4)
binding to the proximal nuclear hormone receptor recognition sequence in the nucleocapsid promoter appears to limit RNA
synthesis from the precore transcription initiation site. Consequently, the variant HBV transgenic mice transcribe very little
precore RNA and secrete extremely low levels of hepatitis B e antigen (HBeAg) compared with the wild-type HBV transgenic
mice. This is consistent with the suggestion that viruses expressing HBeAg are preferentially eliminated in infected
individuals when they seroconvert from HBeAg positive to anti-HBe antibody-positive status, leaving escape HBV variants
that have reduced HBeAg expression. © 2001 Academic PressKey Words: hepatitis B virus; transgenic mice; peroxisome proliferators; peroxisome proliferator-activated receptor;
hepatocyte nuclear factor 4; variants.INTRODUCTION
Hepatitis B virus (HBV) is a hepatotropic virus that
infects man and higher primates (Raney and McLachlan,
1991). The virus is noncytopathic but is associated with
liver disease that results from an immune response di-
rected against the viral antigens (Chisari and Ferrari,
1995a; Chisari, 1997, 2000). In an acute infection, the
immune response resolves the viral infection and elimi-
nates virus from the host. A chronic asymptomatic infec-
tion can occur in individuals who fail to mount an im-
mune response against HBV, whereas a chronic active
infection can result in cases where the immune re-
sponse fails to resolve the viral infection (Chisari and
Ferrari, 1995a,b; Chisari, 2000). In these cases, virus
production and the host immune response coexist in a
dynamic balance that may be perturbed by a variety of
poorly defined factors.
A relatively common occurrence in chronic HBV infec-
tions is the spontaneous seroconversion of patients from
hepatitis B e antigen (HBeAg)-positive to anti-HBe anti-
body-positive status. Seroconversion is often associated
with the resolution of HBV infection. However, this event
1 Publication number 13969-CB from The Scripps Research Institute.
2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (858) 784-2513. E-mail: mclach@scripps.edu.
239does not always result in viral clearance and the reso-
lution of liver disease. It may be associated with a re-
duced viral titer that is usually associated with the se-
lection of viral variants that fail to express normal levels
of HBeAg (Akahane et al., 1990; Naoumov et al., 1992;
Okamoto et al., 1994; Gu¨nther et al., 1999). The most
common mutation associated with this phenomenon is
the T to A transversion introducing an amber stop codon
(TAG) in place of the tryptophan codon 28 (TTG) in the
precore coding region (Akahane et al., 1990; Naoumov et
al., 1992; Gu¨nther et al., 1999). The premature termination
of the precore polypeptide prevents HBeAg synthesis.
Nucleocapsid promoter mutations that inhibit transcrip-
tion initiation from the precore RNA initiation site but not
from the pregenomic RNA initiation site are also rela-
tively common mutations associated with seroconver-
sion from HBeAg-positive to anti-HBe antibody-positive
status in infected individuals. The most common nucleo-
capsid promoter mutation associated with reduced pre-
core RNA synthesis and concomitant lower HBeAg syn-
thesis is the A1764T plus G1766A mutation located in the
proximal nuclear hormone receptor recognition site
(Okamoto et al., 1994; Gu¨nther et al., 1999).
The proximal nuclear hormone receptor recognition
site has been shown to bind several transcription factors
including HNF4, RXR-peroxisome proliferator-activated
receptor a (PPAR), COUPTF1, and ARP1. HNF4 and the
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240 RANEY ET AL.RXRa-PPARa heterodimer have been shown to activate
transcription from the nucleocapsid promoter using re-
porter gene constructs (Raney et al., 1997). In an HBV
replication assay utilizing nonhepatoma cell lines, it has
been demonstrated that the nuclear hormone receptors,
HNF4 and RXRa-PPARa, are essential determinants of
viral replication, indicating the importance of these tran-
scription factors for viral transcription and replication
(Tang and McLachlan, 2001). In addition, it has been
shown that peroxisome proliferators can activate viral
replication in HBV transgenic mice in a PPARa-depen-
ent manner, demonstrating an in vivo role for PPARa in
he HBV life cycle (Guidotti et al., 1999). The observation
hat the A1764T plus G1766A nucleotide substitutions
ocated in the proximal nuclear hormone receptor recog-
ition site of the nucleocapsid promoter inhibit the RXRa-
PARa heterodimer from binding to this recognition site
Tang et al., 2001) suggested that this variant viral ge-
ome may display altered responsiveness to peroxisome
roliferators in vivo.
In this study, an HBV transgenic mouse was produced
hat contains the A1764T plus G1766A mutation in the
roximal nuclear hormone receptor recognition site of
he nucleocapsid promoter. As observed in wild-type
BV transgenic mice, HBV transcription and replication
ere observed in both the liver and the kidney. The level
f viral replication in the variant HBV transgenic mice
as considerably lower than was observed in the wild-
ype HBV transgenic mice. The difference in the levels of
eplication observed in the livers of the wild-type versus
he variant HBV transgenic mice can be accounted for, in
art, by the number of hepatocytes expressing viral
olypeptides. Importantly, the variant HBV transgenic
ice displayed increased levels of viral transcription and
eplication in response to peroxisome proliferators. This
ndicates that, as previously observed in cell culture
Tang and McLachlan, 2001; Tang et al., 2001), the prox-
mal nuclear hormone receptor recognition site in the
ucleocapsid promoter is important but not essential for
he peroxisome proliferator-mediated increase in viral
ranscription and replication in vivo. The increases in
iral transcription and replication must result from tran-
criptional changes mediated by PPARa either through
the HBV enhancer 1 nuclear hormone receptor recogni-
tion site or as a result of alterations in the physiological
state of the hepatocytes in response to peroxisome pro-
liferators. Regardless of the mechanism of action of the
peroxisome proliferators, the relative level of the precore
and pregenomic RNAs was not altered by the activation
of PPARa in vivo. Transient transfection analysis using
the variant HBV genome suggests that HNF4 binding to
the proximal nuclear hormone receptor recognition se-
quence in the nucleocapsid promoter may control the
relative frequency of transcription initiation from the pre-
core and pregenomic RNA start sites. In addition, nuclear
hormone receptors, including RXRa-PPARa hetero-dimers, binding to the enhancer 1 region may modulate
the level of transcription from the nucleocapsid promoter.
The different effects nuclear hormone receptors have in
governing the absolute and relative levels of the precore
and pregenomic RNAs transcribed from wild-type and
variant genomes may be important when considering the
mechanisms of variant HBV selection in natural infection.
RESULTS
The production and characterization of the wild-type
HBV transgenic mouse lineage 1.3.32 has been de-
scribed (Guidotti et al., 1995). These HBV transgenic
ice contain a single copy of the terminally redundant,
.3-genome-length copy of the wild-type HBVayw ge-
ome integrated into the mouse chromosomal DNA.
igh levels of HBV replication occur in the livers of these
ice. The variant HBV transgenic mouse lineages TA910
nd TA808 used in these studies were produced using
he variant HBV DNA (4.1 kbp) construct (Fig. 1). The HBV
NA (4.1 kbp) construct contains 1.3 copies of the HBV
enome and includes the viral sequences from nucleo-
ide coordinates 1072 to 3182 and 1 to 1990 (Fig. 1) (Tang
nd McLachlan, 2001). The HBV sequences present in
his construct are essentially identical to those used to
enerate the HBV transgenic mouse lineage 1.3.32
Guidotti et al., 1995). The variant HBV genome contains
the nucleotide substitutions A1764T and G1766A (Fig. 1B)
introduced into the HBV DNA (4.1 kb) construct. The
nucleotide substitutions converted the 13 nucleotide di-
rect repeat 1 (DR1) nuclear hormone receptor recogni-
tion site sequence located between 228 and 216 (nu-
cleotide coordinates 1757 to 1769) relative to the precore
RNA initiation site from AGGTTAAAGGTCT to AGGTTA-
AtGaTCT (Fig. 1B). The variant sequence was introduced
into the nucleocapsid promoter regions of the HBV ge-
nome at both the 59 and 39 ends of the HBV DNA (4.1 kb)
construct.
Identification of the founder variant HBV transgenic
mice
Six founder variant HBV transgenic mice were identi-
fied by PCR analysis of tail DNA (Fig. 1). The levels of
hepatitis B surface antigen (HBsAg) and HBeAg in the
sera of these six mice were too low to reliably determine
whether they were expressing viral proteins. Therefore
the six lineages of mice were expanded by backcrossing
against the C57BL/6 parental strain. Variant HBV trans-
genic mice were identified by PCR analysis of tail DNA
and subsequently analyzed for viral transcripts and rep-
lication intermediates in their livers and kidneys. Four of
the variant HBV transgenic mice lineages did not show
any evidence of viral transcription or replication in either
tissue and were not characterized further. The variant
HBV transgenic mice of the TA910 lineage, possessing a
single copy of the variant HBV transgene DNA (A. K.
indicat
r core
241IN VIVO REGULATION OF HBV REPLICATIONRaney and A. McLachlan, unpublished data), display
modest levels of the HBV 2.1- and 3.5-kb transcripts in
both liver and kidney (Fig. 2A). Very low levels of the viral
transcripts were also apparent in stomach (Fig. 2A). The
expression of the HBV transcripts in liver and kidney was
associated with a very modest level of viral replication in
these tissues (Fig. 2B). The variant HBV transgenic mice
of the TA808 lineage displayed levels of the HBV 2.1- and
3.5-kb transcripts in kidney that were approximately
FIG. 1. Structure and sequence of the variant HBV genome used to
HBV DNA (4.1 kbp) construct used to generate the variant HBV transge
construct spans coordinates 1072–3182/1–1990 of the HBV genome (su
indicated. EnhI/Xp, enhancer 1/X-gene promoter region; Cp, nucleoc
promoter; Sp, major surface antigen promoter; X, X gene; S, surface an
Sequence of the HBV core promoter region. Both core promoter region
mutation (A1764T plus G1766A) located in the HNF4 site (nuclear horm
nucleotide substitutions alter the X-gene polypeptide sequence at ami
of the X gene (X-ORF) and precore (PC-ORF) open reading frame are
initiation sites for the HBV 3.5-kb precore (PC RNA) and pregenomic oequivalent to the levels observed in the wild-type HBV
transgenic mice of the 1.3.32 lineage (Fig. 2C). Very lowlevels of the viral transcripts were also apparent in the
stomach (Fig. 2C). However, HBV transcripts were not
apparent in the liver of these mice (Fig. 2C). The expres-
sion of the HBV transcripts in kidney was associated
with a very modest level of viral replication in this tissue
(Fig. 2D). The variant HBV transgenic mice of the TA808
lineage, which possesses two copies of the variant HBV
transgene DNA (A. K. Raney and A. McLachlan, unpub-
lished data), were not characterized further due to the
te the TA808 and TA910 transgenic mice lineages. (A) Structure of the
e. The 4.1-kb greater-than-genome length HBV DNA sequence in this
yw). The locations of the HBV 3.5-, 2.4-, 2.1-, and 0.7-kb transcripts are
r core promoter; pA, polyadenylation site; PS1p, presurface antigen
ene; C, core gene; P, polymerase gene; ORF, open reading frame. (B)
is terminally redundant HBV construct (Fig. 1A) were mutated. The TA
eptor recognition site) is indicated above the wild-type sequence. The
positions 130 and 131 (K130M and V131I). The amino acid sequence
ed. The HNF3 and Sp1 binding sites are indicated. The transcription
(C RNA) RNAs are also indicated.genera
nic mic
btype a
apsid o
tigen g
s in th
one rec
no acidlack of viral replication in the liver of these mice.
The generation of the variant HBV transgenic mice of
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e
1
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t conta
242 RANEY ET AL.the TA910 lineage (subsequently designated TA910 trans-
genic mice) permits the further characterization of the
properties of the A1764T and G1766A nucleotide substi-
tutions in the liver-specific regulation of HBV transcrip-
tion and replication in vivo. Comparison of the level of
transcription and replication observed in the liver of
wild-type and variant HBV mice under normal physiolog-
ical conditions indicates that the nucleotide substitutions
within the nucleocapsid promoter may reduce the level
of transcription and consequently replication of this viral
variant within the liver. However the fact that only two
variant HBV transgenic mice lineages were established
that express viral transcripts in either liver or kidney
limits the interpretation of these results. The observation
that the level of expression of the viral genome in liver
and kidney in the variant HBV transgenic mice lineages
is different indicates that the site of viral integration into
the mouse chromosome is a factor influencing viral gene
expression in this system (Fig. 2). The TA910 transgenic
mice did not display any cytopathic effects in the liver
(A. K. Raney and A. McLachlan, unpublished data). This
indicates the nucleotide substitutions do not generate a
FIG. 2. RNA (Northern) and DNA (Southern) filter hybridization analys
in the tissues of HBV transgenic mice. Wild-type HBV transgenic mice
Variant HBV transgenic mice of lineage TA910 (A and B) and TA808 (C a
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcript are in
replication intermediates (RC HBV DNA), and the HBV single-stranded
was digested with HindIII (B and D). HBV DNA (subtype ayw) does nocytopathic viral variant, although this suggestion must be
interpreted with caution given the low level of replication
tobserved in the liver of the TA910 transgenic mice and
the analysis is limited to a single lineage of variant HBV
transgenic mice.
Effect of peroxisome proliferators on HBeAg
synthesis in variant HBV transgenic mice
The nucleocapsid promoter directs the expression of
the precore and pregenomic RNAs that are translated to
produce HBeAg and the nucleocapsid polypeptide, re-
spectively (Raney and McLachlan, 1991). Consequently,
HBeAg expression is an indirect measure of nucleocap-
sid promoter activity. Therefore, analysis of HBeAg in the
sera of TA910 transgenic mice was initially used to ex-
amine the role of peroxisome proliferators in the regula-
tion of HBV transcription from the variant nucleocapsid
promoter. TA910 transgenic mice were treated with two
synthetic PPARa ligands, clofibric acid and Wy-14643
Forman et al., 1997). Following treatment for 7 days, age,
ex, and HBeAg-matched TA910 transgenic mice were
xamined for liver size and serum HBeAg levels (Table
). As previously described, these peroxisome prolifera-
BV transcripts (A and C) and DNA replication intermediates (B and D)
1 and 2) are compared with variant HBV transgenic mice (lanes 3–11).
were analyzed. The positions of the HBV 3.5- and 2.1-kb RNAs and the
d. The positions of the HBV transgene (TG), the HBV relaxed circular
ion intermediates (SS HBV DNA) are also indicated. Total mouse DNA
in any HindIII restriction sites.is of H
(lanes
nd D)
dicateors induce a PPARa-dependent hepatomegaly (Lee et
al., 1995) due to hypertrophy of hepatocytes and hepato-
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243IN VIVO REGULATION OF HBV REPLICATIONcellular hyperplasia (Reddy and Chu, 1996). Hepatocel-
lular hypertrophy is the primary cause of hepatomegaly
and results from a massive increase in peroxisomes
within the hepatocytes (Reddy and Chu, 1996). Control
TA910 transgenic mice have very low serum HBeAg lev-
els (Table 1). Treatment of TA910 transgenic mice with
clofibric acid or Wy-14643 for 7 days resulted in an
approximate 1.5- or 2.4-fold increase in the size of the
liver, respectively, and a modest increase in serum
HBeAg (Table 1). The increase in serum HBeAg with
peroxisome proliferators occurred in every individual
TA910 transgenic mouse examined and was more pro-
nounced in mice treated with Wy-14643. Control TA910
transgenic mice did not show a change in the level of
serum HBeAg during the 7 day period examined. These
observations are consistent with the possibility that ac-
tivation of PPARa by peroxisome proliferators in TA910
ransgenic mice results in increased transcription from
he nucleocapsid promoter and therefore increased lev-
ls of the precore RNA.
ffect of peroxisome proliferators on viral
ranscription and replication in variant HBV
ransgenic mice
The TA910 transgenic mice described above were
xamined for the effects of peroxisome proliferators on
he steady state levels of HBV transcripts and replication
ntermediates by analysis of the total liver RNA and DNA
Fig. 3). Induction of the PPARa-responsive cytochrome
450 4A (CYP4A) mRNA by the peroxisome proliferators,
lofibric acid and Wy-14643, confirmed that these com-
ounds mediated PPARa-dependent transcriptional acti-
vation of responsive genes in the TA910 transgenic mice
T
Effect of Peroxisome Proliferators on HBeAg Synthe
Sex Treatmenta
Liver size (%)b
Mean (SD)
M Control 4.89 (0.24)
M CA 7.67 (1.16)
M Wy 11.16 (0.61)
F Control 4.75 (0.20)
F CA 6.38 (0.62)
F Wy 11.58 (0.92)
a Variant HBV transgenic mice of the TA910 lineage (four mice per g
w/w) clofibric acid (CA) or 0.1% (w/w) Wy-14,643 (Wy).
b The mean (and standard deviation) liver size represents the perce
c The mean (and standard deviation) absorbance at 492 nm of 20
immunoassay immediately prior to (day 0) the treatment of the mice.
d The mean (and standard deviation) absorbance at 492 nm of 2
immunoassay on day 7 of the treatment of the mice.
e The ratio of the mean absorbances for HBeAg on day 7 to day 0.
f The increase in serum HBeAg resulting from peroxisome proliferat(Fig. 3C) (Lee et al., 1995). Analysis of the levels of the
HBV 3.5- and 2.1-kb transcripts in the livers of TA910
g
ytransgenic mice in the presence or absence of peroxi-
some proliferators was performed. The steady state lev-
els of the HBV transcripts increase between two- and
fivefold in response to peroxisome proliferator treatment
(Fig. 3B and Table 2). This modest induction of the HBV
RNAs is consistent with the presence of a functional
peroxisome proliferator response element (PPRE) in the
enhancer 1 region that can mediate the increase in
transcription from the HBV promoters (Huan et al., 1995;
ang and McLachlan, 2001). However, as this analysis
as conducted on a single lineage of variant HBV trans-
enic mice, an effect resulting from the transgene inte-
ration site cannot be excluded. The induction of viral
eplication by the peroxisome proliferators was more
ramatic than the induction of the HBV RNAs. The very
ow level of viral replication in the untreated TA910 trans-
enic mice made an accurate determination of the abun-
ance of the HBV DNA replication intermediates in these
ice difficult. However it is apparent that the intrahepatic
eplication intermediates increased at least 10-fold in
esponse to peroxisome proliferators (Fig. 3 and Table 2).
his suggests that the viral replication intermediates do
ot increase in a linear manner relative to the level of the
BV 3.5-kb RNA as the modest increase in viral RNA is
ssociated with a much larger increase in intracellular
BV DNA in the TA910 transgenic mice.
The relative abundance of the precore and pre-
enomic 3.5-kb RNAs in HBV transgenic mice was in-
estigated to determine whether activation of PPARa by
eroxisome proliferators affected the relative utilization
f the two start sites (Fig. 4). Treatment with the peroxi-
ome proliferators, clofibric acid or Wy-14643, did not
lter the relative abundance of the precore and pre-
Variant HBV Transgenic Mice of the TA910 Lineage
A492 (d0)
c
an (SD)
HBeAg A492 (d7)
d
Mean (SD)
Mean HBeAg
fold inductione
5 (0.005) 0.052 (0.005) 0.69
7 (0.003) 0.079 (0.013) 1.18
3 (0.012) 0.289 (0.164) 3.99 f
5 (0.066) 0.088 (0.080) 1.04
6 (0.007) 0.087 (0.023) 1.89 f
1 (0.025) 0.129 (0.061) 2.55 f
ere fed normal rodent chow (Control) or rodent chow containing 0.5%
f the total body weight contributed by the liver of the mouse.
ra assayed for HBeAg using the Abbott Laboratories HBe enzyme
ra assayed for HBeAg using the Abbott Laboratories HBe enzyme
ment is statistically significant by a paired Student’s t-test (P , 0.05).ABLE 1
sis in
HBeAg
Me
0.07
0.06
0.07
0.08
0.04
0.05
roup) w
ntage o
ml se
0 ml seenomic RNAs as determined by RNase protection anal-
sis. The pregenomic RNA initiation site is utilized ap-
np
c
r
e
v
sgenic
f
244 RANEY ET AL.proximately five times more than the precore RNA initi-
ation site in wild-type HBV transgenic mice irrespective
of the presence of peroxisome proliferators (Fig. 4, lanes
1–3). Similarly, the pregenomic RNA initiation site is uti-
lized approximately 25 times more than the precore RNA
initiation site in TA910 transgenic mice, irrespective of
the presence of peroxisome proliferators (Fig. 4, lanes
4–15). These observations demonstrate that the nucleo-
tide substitutions in the proximal nuclear hormone re-
ceptor recognition site in the nucleocapsid promoter
reduce the relative frequency of initiation approximately
fivefold from the precore RNA initiation site in this animal
model.
FIG. 3. DNA (Southern) and RNA (Northern) filter hybridization analy
of variant HBV transgenic mice of the TA910 lineage. Groups of five mic
with the peroxisome proliferators, clofibric acid or Wy-14643, for 7 days
the rat cytochrome P450 4A1 cDNA (4A1) was used as a control to dem
proliferators from a responsive gene. The glyceraldehyde 3-phosphate
the quantitation of the HBV 3.5- and 2.1-kb RNAs. The HBV transgene (T
intermediates. The probes used were HBVayw genomic DNA (A), HBV
GAPDH cDNA (C). TG 5 HBV transgene; RC HBV DNA 5 HBV relax
replication intermediates; Male 5 male HBV transgenic mouse; Fem
transgenic mice fed untreated rodent chow; clofibric acid 5 TA910 tran
ed 0.1% (w/w) Wy-14643.It is noteworthy that activation of PPARa in vivo does
ot affect the relative levels of transcription from the
t
srecore and pregenomic RNA initiation sites (Fig. 4). This
ontrasts with the results from cell culture where PPARa
preferentially increases transcription from the precore
RNA initiation site of the variant HBV genome (Tang et al.,
2001). The reason for the difference may be due to the
coexistence of HNF4 and PPARa in the liver of the variant
HBV transgenic mice. To examine this possibility, wild-
type and variant HBV DNA (4.1 kbp) constructs (Fig. 1)
were transfected into mouse NIH 3T3 fibroblast with
HNF4, RXRa, and PPARa expression vectors and the
elative levels of the precore and pregenomic RNAs were
xamined by RNase protection analysis (Fig. 5). As pre-
iously described (Tang et al., 2001), the relative levels of
BV DNA replication intermediates (A) and transcripts (B) in the livers
ch sex and genotype were fed rodent chow either untreated or treated
their livers were analyzed. The induction of the transcript detected by
te the PPARa-dependent activation of transcription by the peroxisome
rogenase (GAPDH RNA) transcript was used as an internal control for
used as an internal control for the quantitation of the HBV replication
enomic DNA plus GAPDH cDNA (B), and cytochrome P450 4A1 plus
ular replication intermediates; SS HBV DNA 5 HBV single-stranded
female HBV transgenic mouse; Peroxisome proliferator 2 5 TA910
mice fed 0.5% (w/w) clofibric acid; Wy-14643 5 TA910 transgenic micesis of H
e of ea
before
onstra
dehyd
G) was
ayw g
ed circ
ale 5he precore (PC) and pregenomic or core (C) RNAs were
imilar regardless of the nuclear hormone receptor me-
v
C
P
0
H
245IN VIVO REGULATION OF HBV REPLICATIONdiating transcription from the wild-type nucleocapsid
promoter (Fig. 5, lanes 2–4, PC/C ratio ’ 0.5). In contrast,
HNF4 binds the proximal nuclear hormone receptor rec-
ognition site of the variant nucleocapsid promoter and
preferentially supports transcription of the pregenomic
RNA (Fig. 5, lane 6, PC/C ratio ’ 0.2). RXRa-PPARa
cannot bind the proximal nuclear hormone receptor rec-
ognition site of the variant nucleocapsid promoter and
consequently preferentially supports transcription of the
precore RNA (Fig. 5, lane 7, PC/C ratio ’ 1.4) from the
ariant HBV DNA (4.1 kbp) construct (Tang et al., 2001).
oexpression of HNF4 and RXRa-PPARa results in rela-
tive levels of precore and pregenomic RNA expression
(Fig. 5, lane 8, PC/C ratio ’ 0.3) from the variant HBV
genome that are similar to the relative levels observed
with HNF4 alone. The observed relative levels of precore
and pregenomic RNAs are quite different from the levels
predicted for the independent activation of transcription
by HNF4 and RXRa-PPARa from the variant HBV genome
(PC/C ratio ’ 0.8 represents the sum of the PC RNAs
from Fig. 5, lanes 6 and 7, divided by the sum of the C
RNAs from Fig. 5, lanes 6 and 7). This supports the
suggestion that in the presence of both HNF4 and RXRa-
PARa the binding of HNF4 to the proximal nuclear
hormone receptor recognition site in the variant nucleo-
capsid promoter determines the relative levels of the
precore and pregenomic RNAs. In contrast, peroxisome
proliferators increase the level of both the HBV 3.5-kb
RNAs by activating PPARa bound to the nuclear hormone
T
Effect of Clofibric Acida and Wy-14,643a on Liver HBV RNA and
Group
Male mice
untreateda
Male
1C
HBV 2.1-kb RNA to GAPDH RNA ratiob (SD) 0.17 (0.04) 0.45
Fold induction of HBV 2.1-kb RNAc 2
HBV 3.5-kb RNA to GAPDH RNA ratiob (SD) 0.15 (0.01) 0.31
Fold induction of HBV 3.5-kb RNAc 2
RI to TG ratio (SD)d 0.01 (0.02) 0.65
Fold induction of HBV RIe 6
a Variant HBV transgenic mice of the TA910 lineage (five mice per gro
.5% (w/w) clofibric acid (1CA) or 0.1% (w/w) Wy-14,643 (1Wy) for 7 d
BV transgene (TG), and replication intermediate (RI) DNAs in the live
b Means (and standard deviations) of the levels of the HBV 2.1- and
c The fold induction of the HBV 2.1- and 3.5-kb RNAs were determine
untreated mice.
d Means (and standard deviations) of the levels of the HBV replicatio
determined from Fig. 3A.
e The fold induction of the HBV replication intermediate DNA was d
untreated mice.
f The increases in HBV RNAs and DNA resulting from clofibric acid orreceptor recognition element in the enhancer 1 region
(Figs. 3, 4, and 5).Effect of peroxisome proliferators on viral HBcAg
distribution within the livers of variant HBV transgenic
mice of the TA910 lineage
Immunohistochemical analysis of the livers of TA910
transgenic mice demonstrated that only a very limited
number of hepatocytes express HBcAg (Fig. 6). This
suggests that the modest levels of HBV RNA and DNA
observed in the livers of the TA910 transgenic mice
compared with the wild-type HBV transgenic mice prob-
ably reflect to a large degree the difference in the num-
ber of cells replicating virus (Figs. 2 and 3). In control
TA910 transgenic mice, nuclear and cytoplasmic HBcAg
was observed only in a few hepatocytes located around
the central vein. Nuclear HBcAg without cytoplasmic
HBcAg was found in cells scattered throughout the liver
lobule but rarely in proximity to the portal vein. This is the
same basic pattern of HBcAg localization observed in
the livers of wild-type HBV transgenic mice (Guidotti et
al., 1995) except that many fewer cells are positive for
antigen in TA910 transgenic mice. Treatment with perox-
isome proliferators influenced the localization of HBcAg
within the hepatocyte (Fig. 6). In both male and female
TA910 transgenic mice, treatment with clofibric acid and
Wy-14643 results in the majority of the antigen-positive
hepatocytes displaying both nuclear and cytoplasmic
HBcAg without significantly more hepatocytes express-
ing antigen (Fig. 6). As cytoplasmic HBcAg staining cor-
relates with viral replication (Guidotti et al., 1995), this
observation is consistent with the increased level of viral
ynthesis in Variant HBV Transgenic Mice of the TA910 Lineage
Male mice
1Wya
Female mice
untreateda
Female mice
1CAa
Female mice
1Wya
0.75 (0.42) 0.13 (0.04) 0.69 (0.35) 0.42 (0.16)
4.4 f 5.3 f 3.2 f
0.53 (0.20) 0.14 (0.01) 0.51 (0.24) 0.33 (0.10)
3.5 f 3.6 f 2.4 f
1.86 (1.08) 0.06 (0.05) 0.85 (0.57) 0.76 (0.25)
186 f 14 f 13 f
e fed normal rodent chow (untreated) or rodent chow containing either
ore the relative levels of the HBV 2.1- and 3.5-kb RNAs, GAPDH RNA,
3) were measured.
RNAs relative to the GAPDH RNA were determined from Fig. 3B.
the ratio of the levels of these transcripts in treated (1CA or 1Wy) to
ediate DNA (RI) relative to the variant HBV transgene DNA (TG) were
ned from the ratio of the levels of the RI in treated (1CA or 1Wy) to
,643 treatment is statistically significant by a Student’s t-test (P , 0.05).ABLE 2
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246 RANEY ET AL.TA910 transgenic mice treated with peroxisome prolifera-
tors display the expected hypertrophy, whereas this ef-
fect and the extended cytoplasmic distribution of HBcAg
staining is not observed in untreated TA910 transgenic
mice (Fig. 6).
DISCUSSION
In cell culture, PPREs have been identified in the HBV
FIG. 4. RNase protection analysis mapping the transcription initiation
sites of the precore (PC) and pregenomic (C) transcripts from the livers
of variant HBV transgenic mice of the TA910 lineage. The 39 end of all
the HBV transcripts corresponding to the polyadenylation site (pA) of
these RNAs also generated a protected fragment in this analysis.
Control wild-type HBV transgenic mice were fed rodent chow either
untreated (lane 2), treated with clofibric acid (lane 1), or Wy-14643 (lane
3) before their livers were analyzed. Groups of four male TA910 mutant
transgenic mice were fed rodent chow either untreated (lanes 4–7),
treated with clofibric acid (lanes 8–11), or Wy-14643 (lanes 12–15) for 7
days before their livers were analyzed. The riboprobe used included
the HBVayw sequence spanning nucleotide coordinates 1990 to 1658.
A riboprobe detecting the ribosomal gene L32 transcript was included
as an internal control. Peroxisome proliferator 2 5 TA910 transgenic
mice fed untreated rodent chow; clofibric acid 5 TA910 transgenic mice
fed 0.5% (w/w) clofibric acid; Wy-14643 5 TA910 transgenic mice fed
0.1% (w/w) Wy-14643.enhancer 1 and nucleocapsid promoter of the virus ge-
nome (Huan et al., 1995; Raney et al., 1997; Yu and Mertz,1997). These nuclear hormone receptor recognition sites
bind HNF4, COUPTF1, and ARP1 in addition to PPAR
(Raney et al., 1997; Buckwold et al., 1997; Yu and Mertz,
1997). Transcription from the nucleocapsid promoter is
regulated by the RXRa-PPARa heterodimer in a ligand-
dependent manner (Raney et al., 1997). Viral replication
in cell culture has also been shown to be highly depen-
dent on the nuclear hormone receptors, HNF4 and RXRa
plus PPARa (Tang and McLachlan, 2001). The nuclear
ormone receptor recognition site in the nucleocapsid
romoter is the most important regulatory element con-
rolling transcription of the HBV 3.5-kb pregenomic RNA
Tang and McLachlan, 2001). In the absence of a func-
ional nuclear hormone receptor recognition site in the
ucleocapsid promoter, RXRa plus PPARa can support
viral replication, presumably through interaction with the
FIG. 5. Effect of liver-enriched transcription factors on the initiation
site of the HBV 3.5-kb RNA transcribed from the wild-type and variant
HBV genomes. Mouse NIH 3T3 fibroblasts were transiently transfected
with the wild-type HBV DNA (4.1 kbp) construct (lanes 1–4) and the
variant HBV DNA (4.1 kbp) construct (lanes 5–8) plus liver-enriched
transcription factors as indicated. RNase protection analysis was per-
formed to map the transcription initiation sites of the HBV precore (PC)
and pregenomic or core (C) transcripts. The HBV probe also protected
a fragment (pA) derived from the 39 end of all the HBV RNAs that
terminated at the HBV polyadenylation site. A riboprobe detecting the
ribosomal gene L32 transcripts was included as an internal control.
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247IN VIVO REGULATION OF HBV REPLICATIONnuclear hormone receptor recognition site located in the
enhancer 1 region (Huan et al., 1995; Tang and
McLachlan, 2001). The analysis of the role of PPARa in
egulating HBV transcription and replication has been
xtended to the HBV transgenic mouse model. In this in
ivo model, peroxisome proliferators have been shown to
ncrease HBV replication in a PPARa-dependent manner
Guidotti et al., 1999). These results indicate that PPARa,
when activated by its ligand, is an important regulator of
FIG. 6. Immunohistochemical staining of HBcAg in the livers of varia
Nuclear staining of HBcAg is observed in a few hepatocytes throu
centrolobular hepatocytes in the livers of untreated TA910 transgenic m
middle) or Wy-14643 (bottom) results in hepatocyte hypertrophy and
hepatocytes but is apparent in only a few hepatocytes. The yellow sizHBV transcription and replication.
A relatively common HBV variant that is often found in
T
rpatients who have seroconverted from HBeAg positive to
anti-HBe antibody-positive status contains two nucleo-
tide substitutions (A1764T and G1766A) in the nuclear
hormone receptor recognition site in the nucleocapsid
promoter (Okamoto et al., 1994; Gu¨nther et al., 1999). In
vitro DNA binding analysis demonstrated that the pri-
mary effect of the two nucleotide substitutions is to
inhibit the binding of the RXRa-PPARa heterodimer to
his variant nuclear hormone receptor recognition site.
transgenic mice of the TA910 lineage (Original magnification, 3200).
the liver, whereas cytoplasmic staining is located primarily in the
). Treatment of TA910 mutant transgenic mice with clofibric acid (1CA,
ar plus cytoplasmic HBcAg staining that extends to the periportal
s 500 mm.nt HBV
ghout
ice (tophe efficiency of binding of additional nuclear hormone
eceptors, including HNF4, may also be reduced by the
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248 RANEY ET AL.two nucleotide substitutions (Tang et al., 2001). However,
unctional analysis of the variant nuclear hormone recep-
or recognition site demonstrated that it can mediate
NF4-dependent activation of transcription from a mini-
al promoter directing the expression of a reporter gene.
n contrast, the variant nuclear hormone receptor recog-
ition site failed to mediate RXRa-PPARa-dependent
transcription from the same reporter gene construct as
expected from the DNA binding studies. In addition,
RXRa-PPARa-regulated viral replication is reduced from
he variant HBV genome, indicating that this mutation
lters the responsiveness of the viral genome to activa-
ion by PPARa in cell culture (Tang et al., 2001).
The difference in the ability of PPARa to modulate
replication from wild-type and the variant HBV genomes
in cell culture suggested that these viruses might be
differentially regulated in vivo. This possibility was inves-
tigated by generating an HBV transgenic mouse with the
variant HBV genome (TA910 lineage). The level of tran-
scription and replication in the livers of the variant HBV
transgenic mice was much lower than that found in the
wild-type HBV transgenic mice (Figs. 2 and 3 and Table
2). This appears to be due in large part to the limited
number of hepatocytes that were expressing viral anti-
gens in the variant HBV transgenic mice (Fig. 6) and may
reflect the integration site of the transgene.
Analysis of the HBV 3.5-kb RNAs demonstrated that
the TA910 transgenic mice produce approximately 25-
fold less precore RNA relative to pregenomic RNA (Fig.
4). This observation can help to explain the very low
levels of HBeAg present in the sera of TA910 transgenic
mice (Table 1). Importantly, treatment of variant HBV
transgenic mice with peroxisome proliferators demon-
strated that the levels of both viral transcripts and repli-
cation intermediates were increased in the livers of
these mice. This shows that the variant HBV viral ge-
nome has retained its ability to respond to the activation
of PPARa by its ligands. This suggests that PPARa inter-
acting with the nuclear hormone receptor recognition
site in the enhancer 1 region mediates the peroxisome
proliferator induced increase in transcription and repli-
cation in vivo in a manner similar to that observed in cell
culture (Tang and McLachlan, 2001; Tang et al., 2001).
Alternatively, the altered physiological state of the hepa-
tocyte induced by these compounds may be indirectly
responsible for the observed increase in viral transcrip-
tion and replication. In addition, as a single variant HBV
transgenic mouse lineage was analyzed, it is possible
that the alterations in viral transcription and replication
may be influenced by the site of integration of the trans-
gene into the mouse chromosomal DNA.
As previously observed in the wild-type HBV trans-
genic mice (Guidotti et al., 1999), viral replication in-
creased considerably more than viral transcription. In the
case of the variant HBV transgenic mice, serum HBeAg
and HBV transcripts were increased two- to fivefold,whereas intrahepatic replication intermediates in-
creased more than 10-fold in female mice and probably
more than this in male mice in response to peroxisome
proliferator treatment. This demonstrates that modest
increases in pregenomic RNA can be associated with
considerably larger increases in viral replication, sug-
gesting that HBV DNA synthesis is highly sensitive to
alteration in viral transcription. In addition, the observa-
tion that some untreated variant HBV transgenic mice
displayed measurable levels of viral transcripts but es-
sentially undetectable levels of viral replication suggests
a critical concentration of certain viral products must be
synthesized within the hepatocyte before HBV DNA syn-
thesis can be initiated. A possible candidate for regulat-
ing viral replication in this manner is the pregenomic
RNA encoded core antigen that forms capsids at a crit-
ical polypeptide concentration and inside which replica-
tion occurs (Zhou et al., 1992).
The reason the variant viral genome is often detected
when patients seroconvert from HBeAg positive to anti-
HBe antibody-positive status is unclear. The finding that
the variant genome expresses low levels of the precore
RNA encoding the HBeAg in vivo suggests immune se-
lection reduces or eliminates the wild-type HBV genome
more efficiently than the variant HBV genome. If this
occurs, it could lead to the association of the variant
genome with the anti-HBe antibody-positive status.
The failure of the RXRa-PPARa heterodimer to bind to
the variant nuclear hormone receptor recognition site in
the nucleocapsid promoter might play a role in reducing
the relative level of the precore RNA compared with the
pregenomic RNA in vivo. However, the in vivo results
appear to differ from the previously described situation in
cell culture where RXRa-PPARa supports higher relative
levels of precore RNA synthesis from the variant HBV
genome than the wild-type HBV genome (Tang et al.,
2001). The reason for this apparent difference can be
explained by the presence of both HNF4 and PPARa in
he liver of the transgenic mice. In cell culture and pos-
ibly in vivo, the RXRa-PPARa heterodimer bound to the
enhancer 1 region increases the level of HNF4-activated
transcription from the variant nucleocapsid promoter
without greatly modulating the relative synthesis of the
precore and pregenomic RNAs (Fig. 5). Therefore it ap-
pears that HNF4 binding to the proximal nuclear hor-
mone receptor recognition site of the variant nucleocap-
sid promoter blocks the ability of RXRa-PPARa to support
he relatively high levels of precore RNA synthesis ob-
erved with RXRa-PPARa in the absence of HNF4 (Fig.
5). These results support the suggestion that HNF4 bind-
ing to the proximal nuclear hormone receptor recognition
site in the variant nucleocapsid promoter excludes or
limits the formation of the transcription preinitiation com-
plex that directs the expression of the precore RNA. By
blocking the formation of the transcription preinitiation
complex that directs the expression of the precore RNA,
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249IN VIVO REGULATION OF HBV REPLICATIONHNF4 bound to the proximal nuclear hormone receptor
recognition site of the nucleocapsid promoter may also
enhance the formation of the transcription preinitiation
complex that directs the expression of the pregenomic
RNA (Tang and McLachlan, 2001). In contrast to the in
ivo situation, RXRa-PPARa can be expressed without
HNF4 in cell culture. RXRa-PPARa cannot bind to the
proximal nuclear hormone receptor recognition site of
the variant nucleocapsid promoter and the transcription
preinitiation complex that directs the expression of the
precore RNA may form efficiently in the absence of
HNF4, resulting in the observed relatively high level of
precore RNA (Fig. 5).
Leukotriene B4 has been reported to be one of the
physiological ligands for PPARa (Devchand et al., 1996).
uring chronic HBV infection, Kupffer cells produce leu-
otriene B4 that is catabolized in the hepatocytes by
b-oxidation (Fukai et al., 1996; Denzlinger, 1996). The
uptake of leukotriene B4 by the hepatocytes might acti-
vate PPARa-dependent HBV replication. This putative
echanism of PPARa activation might contribute to a
elective growth advantage for the viral variant com-
ared with the wild-type genome during an immune
esponse if it preferentially activated variant HBV pre-
enomic RNA synthesis in vivo relative to wild-type HBV
regenomic RNA synthesis. The limited analysis with
ild-type (Guidotti et al., 1999) and variant HBV trans-
enic mice suggests peroxisome proliferator treatment
ay increase variant replication more than wild-type
irus biosynthesis supporting this possibility. Regardless
f the mechanism of activation of PPARa, it is apparent
rom these HBV transgenic mouse studies that viral rep-
ication of both genomes is activated in vivo by PPARa in
a ligand-dependent manner. This implies that PPARa
ligands, such as hypolipidemic drugs (Schoonjans et al.,
996; Kroetz et al., 1998; Desvergne and Wahli, 1995;
orman et al., 1997) or dietary and environmental com-
ounds (Schoonjans et al., 1996; Desvergne and Wahli,
995), might modulate HBV replication in patients in-
ected with wild-type and variant viruses although poten-
ially to different extents. This possibility may have clin-
cal implications.
MATERIALS AND METHODS
BV transgenic mice
The production and characterization of the wild-type
BV transgenic mouse lineage 1.3.32 has been de-
cribed (Guidotti et al., 1995). These HBV transgenic
ice contain a single copy of the terminally redundant,
.3-genome-length copy of the wild-type HBVayw ge-
ome integrated into the mouse chromosomal DNA.
igh levels of HBV replication occur in the livers of these
ice. The mice used in this analysis were heterozygousor the HBV transgene and were maintained on the Sv/
29 genetic background.The variant HBV transgenic mouse lineages TA910 and
A808 used in these studies were produced by microin-
ection of the SacI fragment excised from the variant HBV
NA (4.1 kbp) construct (Fig. 1) into C57BL/6 3 BALB/c
2 embryos by conventional technology as previously
escribed (Babinet et al., 1985; Chisari et al., 1985). The
BV DNA (4.1 kbp) construct contains 1.3 copies of the
BV genome and includes the viral sequences from
ucleotide coordinates 1072 to 3182 and 1 to 1990 (Fig. 1)
Tang and McLachlan, 2001). The HBV sequences
resent in this construct are essentially identical to those
sed to generate the HBV transgenic mouse lineage
.3.32 (Guidotti et al., 1995). The variant HBV genome
used for microinjection was produced by introducing the
nucleotide substitutions, A1764T and G1766A (Fig. 1B),
into the HBV DNA (4.1 kbp) construct using the Chame-
leon double-stranded, site-directed mutagenesis kit
(Stratagene Cloning Systems, La Jolla, CA) according to
the manufacturer’s instructions. The nucleotide substitu-
tions converted the 13 nucleotide direct repeat 1 nuclear
hormone receptor recognition site sequence located be-
tween 228 and 216 (nucleotide coordinates 1757 to
1769) relative to the precore RNA initiation site from
AGGTTAAAGGTCT to AGGTTAAtGaTCT (Fig. 1B). The
variant sequence introduced into the nucleocapsid pro-
moter regions of the HBV genome at the 59 and 39 ends
of the HBV DNA (4.1 kbp) construct were both verified by
dideoxynucleotide sequencing (Sanger et al., 1977).
The founder mice were screened for the HBV trans-
gene by polymerase chain reaction (PCR) analysis of tail
DNA. Tail DNA was prepared by incubating 1 cm tail in
500 ml 100 mM Tris–hydrochloride (pH 8.0), 200 mM
NaCl, 5 mM EDTA, 0.2% (wt/vol) SDS containing 100
mg/ml Proteinase K for 16–20 h at 55°C. Samples were
centrifuged at 14,000 rpm in a microfuge for 5 min and
the supernatant was precipitated with 500 ml isopropa-
nol. DNA was pelleted by centrifugation at 14,000 rpm in
a microfuge for 5 min and subsequently dissolved in
100 ml 5 mM Tris–hydrochloride (pH 8.0), 1 mM EDTA.
The HBV transgene was identified by PCR analysis using
the oligonucleotides, TCGATACCTGAACCTTTACCCCGT-
TGCCCG (oligo XpHNF4–1, HBV coordinates 1133 to
1159) and TCGAATTGCTGAGAGTCCAAGAGTCCTCTT
(oligo CpHNF4–2, HBV coordinates 1683 to 1658), and 1
ml tail DNA. The samples were subjected to 32 amplifi-
cation cycles involving denaturation at 94°C for 1 min,
annealing at 55°C for 1 min, and extension from the
primers at 72°C for 2 min. A PCR product of 551 bp
indicated the presence of the HBV transgene. The 20-ml
reaction conditions used were as described by the man-
ufacturer (Boehringer Mannheim) and contained 2.5 u of
Taq DNA polymerase. The variant HBV transgenic mice
used in subsequent analysis were produced by breeding
the HBV-positive founder mice with nontransgenic
C57BL/6 mice.
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250 RANEY ET AL.HBV DNA and RNA analysis
Total DNA and RNA were isolated from livers and
kidneys of HBV transgenic mice as described (Sambrook
et al., 1989; Chomczynski and Sacchi, 1987). DNA (South-
ern) and RNA (Northern) filter hybridization analyses
were performed using 20 mg HindIII-digested DNA and
10 mg total cellular RNA, respectively, as described
Sambrook et al., 1989). Filters were probed with 32P-
labeled HBVayw genomic DNA (Galibert et al., 1979) to
detect HBV sequences, the human glyceraldehyde
3-phosphate dehydrogenase (GAPDH) cDNA (Tso et al.,
1985) to detect the GAPDH mRNA, and the rat cyto-
chrome P450 4A1 (4A1) cDNA (Lee et al., 1995) to detect
the CYP4A mRNA.
RNase protection assays were performed using the
Pharmingen Riboquant Kit and riboprobes were synthe-
sized using the Ambion Maxiscript Kit as described by
the manufacturers. Transcription initiation sites for the
3.5-kb HBV transcripts were examined using 20 mg total
cellular RNA and a 333- (HBV coordinates 1990 to 1658)
nucleotide-long 32P-labeled HBV riboprobe.
Filter hybridization and RNase protection analysis was
quantitated by phosphorimaging using a Packard Cy-
clone Storage Phosphor System.
Cells and transfections
The mouse NIH 3T3 fibroblast cell line was grown in
RPMI 1640 medium and 10% fetal bovine serum at 37°C
in 5% CO2/air. Transfections for viral RNA analysis were
erformed as previously described (Tang and
cLachlan, 2001; McLachlan et al., 1987) using 10-cm
lates, containing approximately 1 3 106 cells. RNA
isolation was performed 3 days posttransfection. The
transfected DNA mixture was composed of 10 mg of the
ild-type or variant HBV DNA (4.1 kbp) construct plus 1.5
mg of the liver-enriched transcription factor expression
vectors, pCMVHNF4, pRS-hRXRa, and pCMVPPARa-G
Raney et al., 1995, 1997). Controls were derived from
ells transfected with the HBV DNA (4.1 kbp) constructs
nd the pCMV expression vector lacking a liver-enriched
ranscription factor cDNA insert (Raney et al., 1997). All-
rans retinoic acid and clofibric acid at 1 mM and 1 mM,
espectively, were used to activate the nuclear hormone
eceptors, RXRa and PPARa.
Transfected cells from a single plate were used for the
preparation of total cellular RNA as described previously
(Chomczynski and Sacchi, 1987; Summers et al., 1991;
Tang and McLachlan, 2001) with minor modifications.
The cells were lysed in 1.8 ml 25 mM sodium citrate, pH
7.0, 4 M guanidinium isothiocyanate, 0.5% (v/v) sarcosyl,
0.1 M 2-mercaptoethanol. After addition of 0.18 ml 2 M
sodium acetate, pH 4.0, the lysate was extracted with 1.8
ml water-saturated phenol plus 0.36 ml chloroform-
isoamyl alcohol (49:1). After centrifugation for 30 min at
3000 rpm in a Sorval RT6000, the aqueous layer wasprecipitated with 1.8 ml isopropanol. The precipitate was
resuspended in 0.3 ml 25 mM sodium citrate, pH 7.0, 4 M
guanidinium isothiocyanate, 0.5% (v/v) sarcosyl, 0.1 M
2-mercaptoethanol and precipitated with 0.6 ml ethanol.
After centrifugation for 20 min at 14,000 rpm in a micro-
centrifuge, the precipitate was resuspended in 0.3 ml 10
mM Tris–hydrochloride, pH 8.0, 5 mM EDTA, 0.1% (w/v)
sodium lauryl sulfate and precipitated with 45 ml 2 M
sodium acetate plus 0.7 ml ethanol.
HBV antigen analysis
HBeAg analysis was performed using 20 ml mouse
erum and the HBe enzyme immunoassay as described
y the manufacturer (Abbott Laboratories). The level of
ntigen was determined in the linear range of the assay.
mmunohistochemical detection of HBcAg in paraffin-
mbedded mouse liver sections was performed as pre-
iously described (Guidotti et al., 1995).
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